+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Infantile Spasms Therapeutics Market 2024-2028

  • PDF Icon

    Report

  • 154 Pages
  • December 2023
  • Region: Global
  • TechNavio
  • ID: 5916615
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The infantile spasms therapeutics market is forecasted to grow by USD 89.61 mn during 2023-2028, accelerating at a CAGR of 5.41% during the forecast period. The report on the infantile spasms therapeutics market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by advancements in research in neurology and epilepsy, growing demand for infantile spasms therapeutics due to the rising prevalence of infantile spasms and related neurological disorders, and increasing awareness and emphasis on early diagnosis of infantile spasms.

The infantile spasms therapeutics market is segmented as below:

By Route Of Administration

  • Parenteral
  • Oral

By Drug Class

  • Anticonvulsants
  • Corticosteroids
  • Others

By Geographical Landscape

  • North America
  • Europe
  • Asia
  • Rest of World (ROW)
This study identifies the growing interest in gene therapy as one of the prime reasons driving the infantile spasms therapeutics market growth during the next few years. Also, increasing integration of digital health solutions and advancements in infantile spasms therapeutics due to collaborations between pharmaceutical companies, research institutions, and advocacy groups will lead to sizable demand in the market.

The report on the infantile spasms therapeutics market covers the following areas:

  • Infantile spasms therapeutics market sizing
  • Infantile spasms therapeutics market forecast
  • Infantile spasms therapeutics market industry analysis
The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading infantile spasms therapeutics market vendors that include Amneal Pharmaceuticals Inc., Cipla Ltd., Endo International Plc, H Lundbeck AS, Hetero Labs Ltd., Intas Pharmaceuticals Ltd., Jazz Pharmaceuticals Plc, Mallinckrodt Plc, Marinus Pharmaceuticals Inc., MSN Laboratories, Ovid Therapeutics Inc., Sanofi SA, SGPharma Pvt. Ltd., Teva Pharmaceutical Industries Ltd., Zydus Lifesciences Ltd., Anavex Life Sciences Corp., Genix Pharma Pvt. Ltd., Jolly Healthcare, and ORPHELIA Pharma. Also, the infantile spasms therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.

Table of Contents

1 Executive Summary
1.1 Market overview
Exhibit 01: Executive Summary - Chart on Market Overview
Exhibit 02: Executive Summary - Data Table on Market Overview
Exhibit 03: Executive Summary - Chart on Global Market Characteristics
Exhibit 04: Executive Summary - Chart on Market By Geographical Landscape
Exhibit 05: Executive Summary - Chart on Market Segmentation by Route of Administration
Exhibit 06: Executive Summary - Chart on Market Segmentation by Drug Class
Exhibit 07: Executive Summary - Chart on Incremental Growth
Exhibit 08: Executive Summary - Data Table on Incremental Growth
Exhibit 09: Executive Summary - Chart on Vendor Market Positioning
2 Market Landscape
2.1 Market ecosystem
Exhibit 10: Parent market
Exhibit 11: Market Characteristics
3 Market Sizing
3.1 Market definition
Exhibit 12: Offerings of vendors included in the market definition
3.2 Market segment analysis
Exhibit 13: Market segments
3.3 Market size 2023
3.4 Market outlook: Forecast for 2023-2028
Exhibit 14: Chart on Global - Market size and forecast 2023-2028 ($ million)
Exhibit 15: Data Table on Global - Market size and forecast 2023-2028 ($ million)
Exhibit 16: Chart on Global Market: Year-over-year growth 2023-2028 (%)
Exhibit 17: Data Table on Global Market: Year-over-year growth 2023-2028 (%)
4 Historic Market Size
4.1 Global infantile spasms therapeutics market 2018 - 2022
Exhibit 18: Historic Market Size - Data Table on global infantile spasms therapeutics market 2018 - 2022 ($ million)
4.2 Route of Administration Segment Analysis 2018 - 2022
Exhibit 19: Historic Market Size - Route of Administration Segment 2018 - 2022 ($ million)
4.3 Drug Class Segment Analysis 2018 - 2022
Exhibit 20: Historic Market Size - Drug Class Segment 2018 - 2022 ($ million)
4.4 Geography Segment Analysis 2018 - 2022
Exhibit 21: Historic Market Size - Geography Segment 2018 - 2022 ($ million)
4.5 Country Segment Analysis 2018 - 2022
Exhibit 22: Historic Market Size - Country Segment 2018 - 2022 ($ million)
5 Five Forces Analysis
5.1 Five forces summary
Exhibit 23: Five forces analysis - Comparison between 2023 and 2028
5.2 Bargaining power of buyers
Exhibit 24: Chart on Bargaining power of buyers - Impact of key factors 2023 and 2028
5.3 Bargaining power of suppliers
Exhibit 25: Bargaining power of suppliers - Impact of key factors in 2023 and 2028
5.4 Threat of new entrants
Exhibit 26: Threat of new entrants - Impact of key factors in 2023 and 2028
5.5 Threat of substitutes
Exhibit 27: Threat of substitutes - Impact of key factors in 2023 and 2028
5.6 Threat of rivalry
Exhibit 28: Threat of rivalry - Impact of key factors in 2023 and 2028
5.7 Market condition
Exhibit 29: Chart on Market condition - Five forces 2023 and 2028
6 Market Segmentation by Route of Administration
6.1 Market segments
Exhibit 30: Chart on Route of Administration - Market share 2023-2028 (%)
Exhibit 31: Data Table on Route of Administration - Market share 2023-2028 (%)
6.2 Comparison by Route of Administration
Exhibit 32: Chart on Comparison by Route of Administration
Exhibit 33: Data Table on Comparison by Route of Administration
6.3 Parenteral - Market size and forecast 2023-2028
Exhibit 34: Chart on Parenteral - Market size and forecast 2023-2028 ($ million)
Exhibit 35: Data Table on Parenteral - Market size and forecast 2023-2028 ($ million)
Exhibit 36: Chart on Parenteral - Year-over-year growth 2023-2028 (%)
Exhibit 37: Data Table on Parenteral - Year-over-year growth 2023-2028 (%)
6.4 Oral - Market size and forecast 2023-2028
Exhibit 38: Chart on Oral - Market size and forecast 2023-2028 ($ million)
Exhibit 39: Data Table on Oral - Market size and forecast 2023-2028 ($ million)
Exhibit 40: Chart on Oral - Year-over-year growth 2023-2028 (%)
Exhibit 41: Data Table on Oral - Year-over-year growth 2023-2028 (%)
6.5 Market opportunity by Route of Administration
Exhibit 42: Market opportunity by Route of Administration ($ million)
Exhibit 43: Data Table on Market opportunity by Route of Administration ($ million)
7 Market Segmentation by Drug Class
7.1 Market segments
Exhibit 44: Chart on Drug Class - Market share 2023-2028 (%)
Exhibit 45: Data Table on Drug Class - Market share 2023-2028 (%)
7.2 Comparison by Drug Class
Exhibit 46: Chart on Comparison by Drug Class
Exhibit 47: Data Table on Comparison by Drug Class
7.3 Anticonvulsants - Market size and forecast 2023-2028
Exhibit 48: Chart on Anticonvulsants - Market size and forecast 2023-2028 ($ million)
Exhibit 49: Data Table on Anticonvulsants - Market size and forecast 2023-2028 ($ million)
Exhibit 50: Chart on Anticonvulsants - Year-over-year growth 2023-2028 (%)
Exhibit 51: Data Table on Anticonvulsants - Year-over-year growth 2023-2028 (%)
7.4 Corticosteroids - Market size and forecast 2023-2028
Exhibit 52: Chart on Corticosteroids - Market size and forecast 2023-2028 ($ million)
Exhibit 53: Data Table on Corticosteroids - Market size and forecast 2023-2028 ($ million)
Exhibit 54: Chart on Corticosteroids - Year-over-year growth 2023-2028 (%)
Exhibit 55: Data Table on Corticosteroids - Year-over-year growth 2023-2028 (%)
7.5 Others - Market size and forecast 2023-2028
Exhibit 56: Chart on Others - Market size and forecast 2023-2028 ($ million)
Exhibit 57: Data Table on Others - Market size and forecast 2023-2028 ($ million)
Exhibit 58: Chart on Others - Year-over-year growth 2023-2028 (%)
Exhibit 59: Data Table on Others - Year-over-year growth 2023-2028 (%)
7.6 Market opportunity by Drug Class
Exhibit 60: Market opportunity by Drug Class ($ million)
Exhibit 61: Data Table on Market opportunity by Drug Class ($ million)
8 Customer Landscape
8.1 Customer landscape overview
Exhibit 62: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
9 Geographic Landscape
9.1 Geographic segmentation
Exhibit 63: Chart on Market share By Geographical Landscape 2023-2028 (%)
Exhibit 64: Data Table on Market share By Geographical Landscape 2023-2028 (%)
9.2 Geographic comparison
Exhibit 65: Chart on Geographic comparison
Exhibit 66: Data Table on Geographic comparison
9.3 North America - Market size and forecast 2023-2028
Exhibit 67: Chart on North America - Market size and forecast 2023-2028 ($ million)
Exhibit 68: Data Table on North America - Market size and forecast 2023-2028 ($ million)
Exhibit 69: Chart on North America - Year-over-year growth 2023-2028 (%)
Exhibit 70: Data Table on North America - Year-over-year growth 2023-2028 (%)
9.4 Europe - Market size and forecast 2023-2028
Exhibit 71: Chart on Europe - Market size and forecast 2023-2028 ($ million)
Exhibit 72: Data Table on Europe - Market size and forecast 2023-2028 ($ million)
Exhibit 73: Chart on Europe - Year-over-year growth 2023-2028 (%)
Exhibit 74: Data Table on Europe - Year-over-year growth 2023-2028 (%)
9.5 Asia - Market size and forecast 2023-2028
Exhibit 75: Chart on Asia - Market size and forecast 2023-2028 ($ million)
Exhibit 76: Data Table on Asia - Market size and forecast 2023-2028 ($ million)
Exhibit 77: Chart on Asia - Year-over-year growth 2023-2028 (%)
Exhibit 78: Data Table on Asia - Year-over-year growth 2023-2028 (%)
9.6 Rest of World (ROW) - Market size and forecast 2023-2028
Exhibit 79: Chart on Rest of World (ROW) - Market size and forecast 2023-2028 ($ million)
Exhibit 80: Data Table on Rest of World (ROW) - Market size and forecast 2023-2028 ($ million)
Exhibit 81: Chart on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
Exhibit 82: Data Table on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
9.7 US - Market size and forecast 2023-2028
Exhibit 83: Chart on US - Market size and forecast 2023-2028 ($ million)
Exhibit 84: Data Table on US - Market size and forecast 2023-2028 ($ million)
Exhibit 85: Chart on US - Year-over-year growth 2023-2028 (%)
Exhibit 86: Data Table on US - Year-over-year growth 2023-2028 (%)
9.8 Germany - Market size and forecast 2023-2028
Exhibit 87: Chart on Germany - Market size and forecast 2023-2028 ($ million)
Exhibit 88: Data Table on Germany - Market size and forecast 2023-2028 ($ million)
Exhibit 89: Chart on Germany - Year-over-year growth 2023-2028 (%)
Exhibit 90: Data Table on Germany - Year-over-year growth 2023-2028 (%)
9.9 UK - Market size and forecast 2023-2028
Exhibit 91: Chart on UK - Market size and forecast 2023-2028 ($ million)
Exhibit 92: Data Table on UK - Market size and forecast 2023-2028 ($ million)
Exhibit 93: Chart on UK - Year-over-year growth 2023-2028 (%)
Exhibit 94: Data Table on UK - Year-over-year growth 2023-2028 (%)
9.10 France - Market size and forecast 2023-2028
Exhibit 95: Chart on France - Market size and forecast 2023-2028 ($ million)
Exhibit 96: Data Table on France - Market size and forecast 2023-2028 ($ million)
Exhibit 97: Chart on France - Year-over-year growth 2023-2028 (%)
Exhibit 98: Data Table on France - Year-over-year growth 2023-2028 (%)
9.11 China - Market size and forecast 2023-2028
Exhibit 99: Chart on China - Market size and forecast 2023-2028 ($ million)
Exhibit 100: Data Table on China - Market size and forecast 2023-2028 ($ million)
Exhibit 101: Chart on China - Year-over-year growth 2023-2028 (%)
Exhibit 102: Data Table on China - Year-over-year growth 2023-2028 (%)
9.12 Market opportunity By Geographical Landscape
Exhibit 103: Market opportunity By Geographical Landscape ($ million)
Exhibit 104: Data Tables on Market opportunity By Geographical Landscape ($ million)
10 Drivers, Challenges, and Trends
10.1 Market drivers
10.2 Market challenges
10.3 Impact of drivers and challenges
Exhibit 105: Impact of drivers and challenges in 2023 and 2028
10.4 Market trends
11 Vendor Landscape
11.1 Overview
11.2 Vendor landscape
Exhibit 106: Overview on Criticality of inputs and Factors of differentiation
11.3 Landscape disruption
Exhibit 107: Overview on factors of disruption
11.4 Industry risks
Exhibit 108: Impact of key risks on business
12 Vendor Analysis
12.1 Vendors covered
Exhibit 109: Vendors covered
12.2 Market positioning of vendors
Exhibit 110: Matrix on vendor position and classification
12.3 Amneal Pharmaceuticals Inc.
Exhibit 111: Amneal Pharmaceuticals Inc. - Overview
Exhibit 112: Amneal Pharmaceuticals Inc. - Business segments
Exhibit 113: Amneal Pharmaceuticals Inc. - Key news
Exhibit 114: Amneal Pharmaceuticals Inc. - Key offerings
Exhibit 115: Amneal Pharmaceuticals Inc. - Segment focus
12.4 Cipla Ltd.
Exhibit 116: Cipla Ltd. - Overview
Exhibit 117: Cipla Ltd. - Business segments
Exhibit 118: Cipla Ltd. - Key news
Exhibit 119: Cipla Ltd. - Key offerings
Exhibit 120: Cipla Ltd. - Segment focus
12.5 Endo International Plc
Exhibit 121: Endo International Plc - Overview
Exhibit 122: Endo International Plc - Business segments
Exhibit 123: Endo International Plc - Key news
Exhibit 124: Endo International Plc - Key offerings
Exhibit 125: Endo International Plc - Segment focus
12.6 H Lundbeck AS
Exhibit 126: H Lundbeck AS - Overview
Exhibit 127: H Lundbeck AS - Product / Service
Exhibit 128: H Lundbeck AS - Key offerings
12.7 Hetero Labs Ltd.
Exhibit 129: Hetero Labs Ltd. - Overview
Exhibit 130: Hetero Labs Ltd. - Product / Service
Exhibit 131: Hetero Labs Ltd. - Key offerings
12.8 Intas Pharmaceuticals Ltd.
Exhibit 132: Intas Pharmaceuticals Ltd. - Overview
Exhibit 133: Intas Pharmaceuticals Ltd. - Product / Service
Exhibit 134: Intas Pharmaceuticals Ltd. - Key offerings
12.9 Jazz Pharmaceuticals Plc
Exhibit 135: Jazz Pharmaceuticals Plc - Overview
Exhibit 136: Jazz Pharmaceuticals Plc - Product / Service
Exhibit 137: Jazz Pharmaceuticals Plc - Key news
Exhibit 138: Jazz Pharmaceuticals Plc - Key offerings
12.10 Mallinckrodt Plc
Exhibit 139: Mallinckrodt Plc - Overview
Exhibit 140: Mallinckrodt Plc - Business segments
Exhibit 141: Mallinckrodt Plc - Key offerings
Exhibit 142: Mallinckrodt Plc - Segment focus
12.11 Marinus Pharmaceuticals Inc.
Exhibit 143: Marinus Pharmaceuticals Inc. - Overview
Exhibit 144: Marinus Pharmaceuticals Inc. - Product / Service
Exhibit 145: Marinus Pharmaceuticals Inc. - Key offerings
12.12 MSN Laboratories
Exhibit 146: MSN Laboratories - Overview
Exhibit 147: MSN Laboratories - Product / Service
Exhibit 148: MSN Laboratories - Key offerings
12.13 Ovid Therapeutics Inc.
Exhibit 149: Ovid Therapeutics Inc. - Overview
Exhibit 150: Ovid Therapeutics Inc. - Product / Service
Exhibit 151: Ovid Therapeutics Inc. - Key offerings
12.14 Sanofi SA
Exhibit 152: Sanofi SA - Overview
Exhibit 153: Sanofi SA - Business segments
Exhibit 154: Sanofi SA - Key news
Exhibit 155: Sanofi SA - Key offerings
Exhibit 156: Sanofi SA - Segment focus
12.15 SGPharma Pvt. Ltd.
Exhibit 157: SGPharma Pvt. Ltd. - Overview
Exhibit 158: SGPharma Pvt. Ltd. - Product / Service
Exhibit 159: SGPharma Pvt. Ltd. - Key offerings
12.16 Teva Pharmaceutical Industries Ltd.
Exhibit 160: Teva Pharmaceutical Industries Ltd. - Overview
Exhibit 161: Teva Pharmaceutical Industries Ltd. - Business segments
Exhibit 162: Teva Pharmaceutical Industries Ltd. - Key news
Exhibit 163: Teva Pharmaceutical Industries Ltd. - Key offerings
Exhibit 164: Teva Pharmaceutical Industries Ltd. - Segment focus
12.17 Zydus Lifesciences Ltd.
Exhibit 165: Zydus Lifesciences Ltd. - Overview
Exhibit 166: Zydus Lifesciences Ltd. - Business segments
Exhibit 167: Zydus Lifesciences Ltd. - Key offerings
Exhibit 168: Zydus Lifesciences Ltd. - Segment focus
13 Appendix
13.1 Scope of the report
13.2 Inclusions and exclusions checklist
Exhibit 169: Inclusions checklist
Exhibit 170: Exclusions checklist
13.3 Currency conversion rates for US$
Exhibit 171: Currency conversion rates for US$
13.4 Research methodology
Exhibit 172: Research methodology
Exhibit 173: Validation techniques employed for market sizing
Exhibit 174: Information sources
13.5 List of abbreviations
Exhibit 175: List of abbreviations
List of Exhibits
Exhibits 1: Executive Summary - Chart on Market Overview
Exhibits 2: Executive Summary - Data Table on Market Overview
Exhibits 3: Executive Summary - Chart on Global Market Characteristics
Exhibits 4: Executive Summary - Chart on Market By Geographical Landscape
Exhibits 5: Executive Summary - Chart on Market Segmentation by Route of Administration
Exhibits 6: Executive Summary - Chart on Market Segmentation by Drug Class
Exhibits 7: Executive Summary - Chart on Incremental Growth
Exhibits 8: Executive Summary - Data Table on Incremental Growth
Exhibits 9: Executive Summary - Chart on Vendor Market Positioning
Exhibits 10: Parent market
Exhibits 11: Market Characteristics
Exhibits 12: Offerings of vendors included in the market definition
Exhibits 13: Market segments
Exhibits 14: Chart on Global - Market size and forecast 2023-2028 ($ million)
Exhibits 15: Data Table on Global - Market size and forecast 2023-2028 ($ million)
Exhibits 16: Chart on Global Market: Year-over-year growth 2023-2028 (%)
Exhibits 17: Data Table on Global Market: Year-over-year growth 2023-2028 (%)
Exhibits 18: Historic Market Size - Data Table on global infantile spasms therapeutics market 2018 - 2022 ($ million)
Exhibits 19: Historic Market Size - Route of Administration Segment 2018 - 2022 ($ million)
Exhibits 20: Historic Market Size - Drug Class Segment 2018 - 2022 ($ million)
Exhibits 21: Historic Market Size - Geography Segment 2018 - 2022 ($ million)
Exhibits 22: Historic Market Size - Country Segment 2018 - 2022 ($ million)
Exhibits 23: Five forces analysis - Comparison between 2023 and 2028
Exhibits 24: Chart on Bargaining power of buyers - Impact of key factors 2023 and 2028
Exhibits 25: Bargaining power of suppliers - Impact of key factors in 2023 and 2028
Exhibits 26: Threat of new entrants - Impact of key factors in 2023 and 2028
Exhibits 27: Threat of substitutes - Impact of key factors in 2023 and 2028
Exhibits 28: Threat of rivalry - Impact of key factors in 2023 and 2028
Exhibits 29: Chart on Market condition - Five forces 2023 and 2028
Exhibits 30: Chart on Route of Administration - Market share 2023-2028 (%)
Exhibits 31: Data Table on Route of Administration - Market share 2023-2028 (%)
Exhibits 32: Chart on Comparison by Route of Administration
Exhibits 33: Data Table on Comparison by Route of Administration
Exhibits 34: Chart on Parenteral - Market size and forecast 2023-2028 ($ million)
Exhibits 35: Data Table on Parenteral - Market size and forecast 2023-2028 ($ million)
Exhibits 36: Chart on Parenteral - Year-over-year growth 2023-2028 (%)
Exhibits 37: Data Table on Parenteral - Year-over-year growth 2023-2028 (%)
Exhibits 38: Chart on Oral - Market size and forecast 2023-2028 ($ million)
Exhibits 39: Data Table on Oral - Market size and forecast 2023-2028 ($ million)
Exhibits 40: Chart on Oral - Year-over-year growth 2023-2028 (%)
Exhibits 41: Data Table on Oral - Year-over-year growth 2023-2028 (%)
Exhibits 42: Market opportunity by Route of Administration ($ million)
Exhibits 43: Data Table on Market opportunity by Route of Administration ($ million)
Exhibits 44: Chart on Drug Class - Market share 2023-2028 (%)
Exhibits 45: Data Table on Drug Class - Market share 2023-2028 (%)
Exhibits 46: Chart on Comparison by Drug Class
Exhibits 47: Data Table on Comparison by Drug Class
Exhibits 48: Chart on Anticonvulsants - Market size and forecast 2023-2028 ($ million)
Exhibits 49: Data Table on Anticonvulsants - Market size and forecast 2023-2028 ($ million)
Exhibits 50: Chart on Anticonvulsants - Year-over-year growth 2023-2028 (%)
Exhibits 51: Data Table on Anticonvulsants - Year-over-year growth 2023-2028 (%)
Exhibits 52: Chart on Corticosteroids - Market size and forecast 2023-2028 ($ million)
Exhibits 53: Data Table on Corticosteroids - Market size and forecast 2023-2028 ($ million)
Exhibits 54: Chart on Corticosteroids - Year-over-year growth 2023-2028 (%)
Exhibits 55: Data Table on Corticosteroids - Year-over-year growth 2023-2028 (%)
Exhibits 56: Chart on Others - Market size and forecast 2023-2028 ($ million)
Exhibits 57: Data Table on Others - Market size and forecast 2023-2028 ($ million)
Exhibits 58: Chart on Others - Year-over-year growth 2023-2028 (%)
Exhibits 59: Data Table on Others - Year-over-year growth 2023-2028 (%)
Exhibits 60: Market opportunity by Drug Class ($ million)
Exhibits 61: Data Table on Market opportunity by Drug Class ($ million)
Exhibits 62: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
Exhibits 63: Chart on Market share By Geographical Landscape 2023-2028 (%)
Exhibits 64: Data Table on Market share By Geographical Landscape 2023-2028 (%)
Exhibits 65: Chart on Geographic comparison
Exhibits 66: Data Table on Geographic comparison
Exhibits 67: Chart on North America - Market size and forecast 2023-2028 ($ million)
Exhibits 68: Data Table on North America - Market size and forecast 2023-2028 ($ million)
Exhibits 69: Chart on North America - Year-over-year growth 2023-2028 (%)
Exhibits 70: Data Table on North America - Year-over-year growth 2023-2028 (%)
Exhibits 71: Chart on Europe - Market size and forecast 2023-2028 ($ million)
Exhibits 72: Data Table on Europe - Market size and forecast 2023-2028 ($ million)
Exhibits 73: Chart on Europe - Year-over-year growth 2023-2028 (%)
Exhibits 74: Data Table on Europe - Year-over-year growth 2023-2028 (%)
Exhibits 75: Chart on Asia - Market size and forecast 2023-2028 ($ million)
Exhibits 76: Data Table on Asia - Market size and forecast 2023-2028 ($ million)
Exhibits 77: Chart on Asia - Year-over-year growth 2023-2028 (%)
Exhibits 78: Data Table on Asia - Year-over-year growth 2023-2028 (%)
Exhibits 79: Chart on Rest of World (ROW) - Market size and forecast 2023-2028 ($ million)
Exhibits 80: Data Table on Rest of World (ROW) - Market size and forecast 2023-2028 ($ million)
Exhibits 81: Chart on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
Exhibits 82: Data Table on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
Exhibits 83: Chart on US - Market size and forecast 2023-2028 ($ million)
Exhibits 84: Data Table on US - Market size and forecast 2023-2028 ($ million)
Exhibits 85: Chart on US - Year-over-year growth 2023-2028 (%)
Exhibits 86: Data Table on US - Year-over-year growth 2023-2028 (%)
Exhibits 87: Chart on Germany - Market size and forecast 2023-2028 ($ million)
Exhibits 88: Data Table on Germany - Market size and forecast 2023-2028 ($ million)
Exhibits 89: Chart on Germany - Year-over-year growth 2023-2028 (%)
Exhibits 90: Data Table on Germany - Year-over-year growth 2023-2028 (%)
Exhibits 91: Chart on UK - Market size and forecast 2023-2028 ($ million)
Exhibits 92: Data Table on UK - Market size and forecast 2023-2028 ($ million)
Exhibits 93: Chart on UK - Year-over-year growth 2023-2028 (%)
Exhibits 94: Data Table on UK - Year-over-year growth 2023-2028 (%)
Exhibits 95: Chart on France - Market size and forecast 2023-2028 ($ million)
Exhibits 96: Data Table on France - Market size and forecast 2023-2028 ($ million)
Exhibits 97: Chart on France - Year-over-year growth 2023-2028 (%)
Exhibits 98: Data Table on France - Year-over-year growth 2023-2028 (%)
Exhibits 99: Chart on China - Market size and forecast 2023-2028 ($ million)
Exhibits 100: Data Table on China - Market size and forecast 2023-2028 ($ million)
Exhibits 101: Chart on China - Year-over-year growth 2023-2028 (%)
Exhibits 102: Data Table on China - Year-over-year growth 2023-2028 (%)
Exhibits 103: Market opportunity By Geographical Landscape ($ million)
Exhibits 104: Data Tables on Market opportunity By Geographical Landscape ($ million)
Exhibits 105: Impact of drivers and challenges in 2023 and 2028
Exhibits 106: Overview on Criticality of inputs and Factors of differentiation
Exhibits 107: Overview on factors of disruption
Exhibits 108: Impact of key risks on business
Exhibits 109: Vendors covered
Exhibits 110: Matrix on vendor position and classification
Exhibits 111: Amneal Pharmaceuticals Inc. - Overview
Exhibits 112: Amneal Pharmaceuticals Inc. - Business segments
Exhibits 113: Amneal Pharmaceuticals Inc. - Key news
Exhibits 114: Amneal Pharmaceuticals Inc. - Key offerings
Exhibits 115: Amneal Pharmaceuticals Inc. - Segment focus
Exhibits 116: Cipla Ltd. - Overview
Exhibits 117: Cipla Ltd. - Business segments
Exhibits 118: Cipla Ltd. - Key news
Exhibits 119: Cipla Ltd. - Key offerings
Exhibits 120: Cipla Ltd. - Segment focus
Exhibits 121: Endo International Plc - Overview
Exhibits 122: Endo International Plc - Business segments
Exhibits 123: Endo International Plc - Key news
Exhibits 124: Endo International Plc - Key offerings
Exhibits 125: Endo International Plc - Segment focus
Exhibits 126: H Lundbeck AS - Overview
Exhibits 127: H Lundbeck AS - Product / Service
Exhibits 128: H Lundbeck AS - Key offerings
Exhibits 129: Hetero Labs Ltd. - Overview
Exhibits 130: Hetero Labs Ltd. - Product / Service
Exhibits 131: Hetero Labs Ltd. - Key offerings
Exhibits 132: Intas Pharmaceuticals Ltd. - Overview
Exhibits 133: Intas Pharmaceuticals Ltd. - Product / Service
Exhibits 134: Intas Pharmaceuticals Ltd. - Key offerings
Exhibits 135: Jazz Pharmaceuticals Plc - Overview
Exhibits 136: Jazz Pharmaceuticals Plc - Product / Service
Exhibits 137: Jazz Pharmaceuticals Plc - Key news
Exhibits 138: Jazz Pharmaceuticals Plc - Key offerings
Exhibits 139: Mallinckrodt Plc - Overview
Exhibits 140: Mallinckrodt Plc - Business segments
Exhibits 141: Mallinckrodt Plc - Key offerings
Exhibits 142: Mallinckrodt Plc - Segment focus
Exhibits 143: Marinus Pharmaceuticals Inc. - Overview
Exhibits 144: Marinus Pharmaceuticals Inc. - Product / Service
Exhibits 145: Marinus Pharmaceuticals Inc. - Key offerings
Exhibits 146: MSN Laboratories - Overview
Exhibits 147: MSN Laboratories - Product / Service
Exhibits 148: MSN Laboratories - Key offerings
Exhibits 149: Ovid Therapeutics Inc. - Overview
Exhibits 150: Ovid Therapeutics Inc. - Product / Service
Exhibits 151: Ovid Therapeutics Inc. - Key offerings
Exhibits 152: Sanofi SA - Overview
Exhibits 153: Sanofi SA - Business segments
Exhibits 154: Sanofi SA - Key news
Exhibits 155: Sanofi SA - Key offerings
Exhibits 156: Sanofi SA - Segment focus
Exhibits 157: SGPharma Pvt. Ltd. - Overview
Exhibits 158: SGPharma Pvt. Ltd. - Product / Service
Exhibits 159: SGPharma Pvt. Ltd. - Key offerings
Exhibits 160: Teva Pharmaceutical Industries Ltd. - Overview
Exhibits 161: Teva Pharmaceutical Industries Ltd. - Business segments
Exhibits 162: Teva Pharmaceutical Industries Ltd. - Key news
Exhibits 163: Teva Pharmaceutical Industries Ltd. - Key offerings
Exhibits 164: Teva Pharmaceutical Industries Ltd. - Segment focus
Exhibits 165: Zydus Lifesciences Ltd. - Overview
Exhibits 166: Zydus Lifesciences Ltd. - Business segments
Exhibits 167: Zydus Lifesciences Ltd. - Key offerings
Exhibits 168: Zydus Lifesciences Ltd. - Segment focus
Exhibits 169: Inclusions checklist
Exhibits 170: Exclusions checklist
Exhibits 171: Currency conversion rates for US$
Exhibits 172: Research methodology
Exhibits 173: Validation techniques employed for market sizing
Exhibits 174: Information sources
Exhibits 175: List of abbreviations

Executive Summary

The publisher recognizes the following companies as the key players in the global infantile spasms therapeutics market: Amneal Pharmaceuticals Inc., Cipla Ltd., Endo International Plc, H Lundbeck AS, Hetero Labs Ltd., Intas Pharmaceuticals Ltd., Jazz Pharmaceuticals Plc, Mallinckrodt Plc, Marinus Pharmaceuticals Inc., MSN Laboratories, Ovid Therapeutics Inc., Sanofi SA, SGPharma Pvt. Ltd., Teva Pharmaceutical Industries Ltd., Zydus Lifesciences Ltd., Anavex Life Sciences Corp., Genix Pharma Pvt. Ltd., Jolly Healthcare, and ORPHELIA Pharma.

Commenting on the report, an analyst from the research team said: 'The latest trend gaining momentum in the market is growing interest in gene therapy.'

According to the report, one of the major drivers for this market is the advancements in research in neurology and epilepsy.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Amneal Pharmaceuticals Inc.
  • Cipla Ltd.
  • Endo International Plc
  • H Lundbeck AS
  • Hetero Labs Ltd.
  • Intas Pharmaceuticals Ltd.
  • Jazz Pharmaceuticals Plc
  • Mallinckrodt Plc
  • Marinus Pharmaceuticals Inc.
  • MSN Laboratories
  • Ovid Therapeutics Inc.
  • Sanofi SA
  • SGPharma Pvt. Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Zydus Lifesciences Ltd.
  • Anavex Life Sciences Corp.
  • Genix Pharma Pvt. Ltd.
  • Jolly Healthcare
  • ORPHELIA Pharma

Related Topics

Related Reports

Infantile Spasms Therapeutics Global Market Insights 2023, Analysis and Forecast to 2028, by Manufacturers, Regions, Technology, Application, Product Type - Product Image

Infantile Spasms Therapeutics Global Market Insights 2023, Analysis and Forecast to 2028, by Manufacturers, Regions, Technology, Application, Product Type

  • Report
  • 95 Pages
  • Global
From
Global Infantile Spasms Therapeutics Market by Dosage (Liquid, Solid), Route of Administration (Oral, Parental) - Forecast 2024-2030 - Product Image

Global Infantile Spasms Therapeutics Market by Dosage (Liquid, Solid), Route of Administration (Oral, Parental) - Forecast 2024-2030

  • Report
  • 180 Pages
  • Global
From
Global Infantile Spasms Therapeutics Market by Therapeutic Class, Drug Type, Dosage, Route of Administration, Distribution Channel, End User, and Region 2024-2032 - Product Image

Global Infantile Spasms Therapeutics Market by Therapeutic Class, Drug Type, Dosage, Route of Administration, Distribution Channel, End User, and Region 2024-2032

  • Report
  • 137 Pages
  • Global
From
Infantile Spasms Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028F - Product Image

Infantile Spasms Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028F

  • Report
  • 188 Pages
  • Global
From
Infantile Spasm - Pipeline Insight, 2024 - Product Image

Infantile Spasm - Pipeline Insight, 2024

  • Clinical Trials
  • 60 Pages
  • Global
From
Copyright © 2002-2024 Research and Markets. All Rights Reserved.